Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
The Oncologist · 03.06.2024 · 29 (6) · 473-483
DOI: 10.1093/oncolo/oyae046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 23.03.2024. Verfasst von Christopher S Nabel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Thymus Neoplasms, Thymus Gland, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Michelle Cadorette Fund.
Abstract (Originalsprache)
Thymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing immature T-cell production. Against this natural drive toward involution, a fraction of thymuses will instead undergo oncologic transformation, leading to the formation of TETs, including thymoma and thymic carcinoma. The rarity of these tumors restricts investigation of the mechanisms of tumorigenesis and development of rational treatment options. To this end, the development of technologies which allow deep molecular profiling of individual tumor cells permits a new window through which to view normal thymic development and contrast the malignant changes that result in oncogenic transformation. In this review, we describe the findings of recent illuminating studies on the diversity of cell types within the epithelial compartment through thymic differentiation and aging. We contextualize these findings around important unanswered questions regarding the spectrum of known somatic tumor alterations, cell of origin, and tumor heterogeneity. The perspectives informed by single-cell molecular profiling offer new approaches to clinical and basic investigation of thymic epithelial tumors, with the potential to accelerate development of improved therapeutic strategies to address ongoing unmet needs in these rare tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
- Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
- Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Christopher S Nabel, Yin P Hung
Förderung
- NCI NIH HHS
- Michelle Cadorette Fund
Zitieren
APA
Nabel, C. S., Ackman, J. B., Hung, Y. P., Louissaint, A., & Riely, G. J. (2024). Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors. The Oncologist, 29(6), 473-483. https://doi.org/10.1093/oncolo/oyae046
Vancouver
Nabel CS, Ackman JB, Hung YP, Louissaint A, Riely GJ. Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors. The Oncologist. 2024;29(6):473-483. doi:10.1093/oncolo/oyae046
BibTeX
@article{Nabel2024,
author = {Nabel, Christopher S and Ackman, Jeanne B and Hung, Yin P and Louissaint, Abner and Riely, Gregory J},
title = {Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {6},
pages = {473--483},
doi = {10.1093/oncolo/oyae046}
}
EUVIMED